BDSI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BDSI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. BioDelivery Sciences International's Revenue for the three months ended in Dec. 2021 was $43.2 Mil. BioDelivery Sciences International's Total Assets for the quarter that ended in Dec. 2021 was $290.3 Mil. Therefore, BioDelivery Sciences International's Asset Turnover for the quarter that ended in Dec. 2021 was 0.15.
Asset Turnover is linked to ROE % through Du Pont Formula. BioDelivery Sciences International's annualized ROE % for the quarter that ended in Dec. 2021 was 164.56%. It is also linked to ROA % through Du Pont Formula. BioDelivery Sciences International's annualized ROA % for the quarter that ended in Dec. 2021 was 88.02%.
The historical data trend for BioDelivery Sciences International's Asset Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioDelivery Sciences International Annual Data | |||||||||||||||||||||
Trend | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||||
Asset Turnover | Get a 7-Day Free Trial | 0.89 | 0.57 | 0.76 | 0.74 | 0.59 |
BioDelivery Sciences International Quarterly Data | ||||||||||||||||||||
Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | |
Asset Turnover | Get a 7-Day Free Trial | 0.18 | 0.17 | 0.17 | 0.16 | 0.15 |
For the Drug Manufacturers - Specialty & Generic subindustry, BioDelivery Sciences International's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, BioDelivery Sciences International's Asset Turnover distribution charts can be found below:
* The bar in red indicates where BioDelivery Sciences International's Asset Turnover falls into.
Asset Turnover measures how quickly a company turns over its asset through sales.
BioDelivery Sciences International's Asset Turnover for the fiscal year that ended in Dec. 2021 is calculated as
Asset Turnover | ||||||
= | Revenue | / | Average Total Assets | |||
= | Revenue (A: Dec. 2021 ) | / | ( (Total Assets (A: Dec. 2020 ) | + | Total Assets (A: Dec. 2021 )) | / count ) |
= | 166.703 | / | ( (239.894 | + | 324.596) | / 2 ) |
= | 166.703 | / | 282.245 | |||
= | 0.59 |
BioDelivery Sciences International's Asset Turnover for the quarter that ended in Dec. 2021 is calculated as
Asset Turnover | ||||||
= | Revenue | / | Average Total Assets | |||
= | Revenue (Q: Dec. 2021 ) | / | ( (Total Assets (Q: Sep. 2021 ) | + | Total Assets (Q: Dec. 2021 )) | / count ) |
= | 43.154 | / | ( (256.07 | + | 324.596) | / 2 ) |
= | 43.154 | / | 290.333 | |||
= | 0.15 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.
BioDelivery Sciences International (NAS:BDSI) Asset Turnover Explanation
Asset Turnover is linked to ROE % through Du Pont Formula.
BioDelivery Sciences International's annulized ROE % for the quarter that ended in Dec. 2021 is
ROE %** | (Q: Dec. 2021 ) | ||||
= | Net Income | / | Total Stockholders Equity | ||
= | 255.56 | / | 155.2985 | ||
= | (Net Income / Revenue) | * | (Revenue / Total Assets) | * | (Total Assets / Total Stockholders Equity) |
= | (255.56 / 172.616) | * | (172.616 / 290.333) | * | (290.333/ 155.2985) |
= | Net Margin % | * | Asset Turnover | * | Equity Multiplier |
= | 148.05 % | * | 0.5945 | * | 1.8695 |
= | ROA % | * | Equity Multiplier | ||
= | 88.02 % | * | 1.8695 | ||
= | 164.56 % |
Note: The Net Income data used here is four times the quarterly (Dec. 2021) net income data. The Revenue data used here is four times the quarterly (Dec. 2021) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.
It is also linked to ROA % through Du Pont Formula:
BioDelivery Sciences International's annulized ROA % for the quarter that ended in Dec. 2021 is
ROA % | (Q: Dec. 2021 ) | ||
= | Net Income | / | Total Assets |
= | 255.56 | / | 290.333 |
= | (Net Income / Revenue) | * | (Revenue / Total Assets) |
= | (255.56 / 172.616) | * | (172.616 / 290.333) |
= | Net Margin % | * | Asset Turnover |
= | 148.05 % | * | 0.5945 |
= | 88.02 % |
Note: The Net Income data used here is four times the quarterly (Dec. 2021) net income data. The Revenue data used here is four times the quarterly (Dec. 2021) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.
Thank you for viewing the detailed overview of BioDelivery Sciences International's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
James Vollins | officer: See Remarks | C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARK LAKE AVE SUITE 225, RALEIGH NC 27607 |
Mark A Sirgo | director | C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607 |
Broadfin Healthcare Master Fund Ltd | director | C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108 |
Kevin Kotler | director | C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Mary Theresa Coelho | officer: See Remarks | 52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017 |
Jeffrey Allen Bailey | director, officer: Chief Executive Officer | BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612 |
Todd C Davis | director | 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037 |
W. Mark Watson | director | 324 S. HYDE PARK AVENUE, STE 350, TAMPA FL 33606 |
Peter Greenleaf | director | ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878 |
Broadfin Capital, Llc | director | 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Vanila Singh | director | C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612 |
Scott M. Plesha | officer: See Remarks | 1410 SMYTHE ST DANIEL ISLAND SC 29492 |
Odonnell Francis E Jr | director | BIODELIVERY SCIENCES INTERNATIONAL, INC, 4131 PARKLAKE AVENUE, SUITE #225, RALEIGH NC 27612 |
Herm Cukier | director, officer: Chief Executive Officer | C/O BIODELIVERY SCIENTES INT., INC. 4131 PARKLAKE AVE, SUITE 225 RALEIGH NC 27612 |
Thomas B Smith | officer: Chief Medical Officer | BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE SUITE 225, RALEIGH NC 27612 |
From GuruFocus
By PRNewswire PRNewswire • 02-17-2022
By Marketwired Marketwired • 10-20-2021
By PRNewswire PRNewswire • 02-28-2022
By Marketwired Marketwired • 04-20-2021
By PRNewswire PRNewswire • 02-14-2022
By Alberto Abaterusso Alberto Abaterusso • 04-19-2021
By GuruFocusNews GuruFocusNews • 01-20-2022
By GuruFocusNews GuruFocusNews • 02-24-2022
By Marketwired Marketwired • 09-09-2021
By GuruFocusNews GuruFocusNews • 02-14-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.